We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

70 hedge funds and large institutions have $314M invested in Xenon Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

28% more capital invested

Capital invested by funds: $245M → $314M (+$68.7M)

22% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 18

6.96% more ownership

Funds ownership: 72.3% → 79.26% (+7%)

6% more funds holding

Funds holding: 66 → 70 (+4)

Holders
70
Holders Change
+4
Holders Change %
+6.06%
% of All Funds
1.54%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
18
Increased
22
Reduced
18
Closed
13
Calls
$6K
Puts
–
Net Calls
+$6K
Net Calls Change
-$247K

Top Buyers

1
CCM
Consonance Capital Management
New York
+$28.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$22.6M
3
O
OrbiMed
New York
+$14.6M
4
BI
BVF Inc
California
+$10.3M
5
BC
Boxer Capital
California
+$8.54M

Top Sellers

1
ACP
Acuta Capital Partners
California
-$4.12M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.86M
3
SCM
Soleus Capital Management
Connecticut
-$2.11M
4
EP
Eversept Partners
New York
-$2.05M
5
GPCM
Granite Point Capital Management
Massachusetts
-$1.86M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$31.4M +$5.3M +372,000 +16%
BI
2
BVF Inc
California
$30.3M +$10.3M +725,263 +37%
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$23M +$1.42M +100,000 +5%
CCM
4
Consonance Capital Management
New York
$22.4M +$28.2M +1,979,669 New
O
5
OrbiMed
New York
$18.9M +$14.6M +1,028,000 +162%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$18M +$22.6M +1,587,536 New
ACM
7
Aquilo Capital Management
California
$17M +$4.75M +333,234 +29%
EAM
8
Eventide Asset Management
Massachusetts
$14.4M – – –
Capital International Investors
9
Capital International Investors
California
$12M – – –
NMC
10
NEA Management Company
Maryland
$11.3M – – –
Capital World Investors
11
Capital World Investors
California
$10.9M – – –
Renaissance Technologies
12
Renaissance Technologies
New York
$8.94M +$2.74M +192,400 +32%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$7.66M +$6.12M +429,613 +174%
ACP
14
Acuta Capital Partners
California
$7.13M -$4.12M -289,000 -31%
BC
15
Boxer Capital
California
$6.8M +$8.54M +600,000 New
PHP
16
Parkman Healthcare Partners
Connecticut
$6.69M +$31.4K +2,208 +0.4%
Point72 Asset Management
17
Point72 Asset Management
Connecticut
$6.63M -$3.86M -270,747 -32%
Citadel Advisors
18
Citadel Advisors
Florida
$5.74M +$3.9M +273,764 +118%
RSCM
19
Rock Springs Capital Management
Maryland
$5.67M +$7.12M +500,000 New
DCM
20
Driehaus Capital Management
Illinois
$5.24M +$6.58M +462,332 New
IC
21
Ikarian Capital
Texas
$5.03M +$2.85M +200,112 +82%
VC
22
Vivo Capital
California
$4.5M +$5.65M +396,589 New
DCM
23
DAFNA Capital Management
California
$3.93M +$1.39M +97,681 +39%
GTC
24
Ghost Tree Capital
New York
$3.69M +$4.63M +325,000 New
Millennium Management
25
Millennium Management
New York
$2.19M +$2.08M +145,855 +306%
1
2 3 4

XENE Hedge Fund Activity: Q1 2020 in Review

70 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2020, worth a combined $314M — up 28% from $245M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new XENE positions and 13 closed out — a net gain of 5 holders — while 22 added to existing stakes and 18 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $28.2M. The largest seller was Acuta Capital Partners, cutting an estimated $4.12M.

  • 70 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2020, up from 66 in Q4 2019.
  • Funds reported $314M of Xenon Pharmaceuticals stock for Q1 2020, up 28% quarter-over-quarter.
  • 18 funds opened new Xenon Pharmaceuticals positions in Q1 2020 and 13 closed out, a net change of +5 holders.
  • The largest Xenon Pharmaceuticals buyer in Q1 2020 was Consonance Capital Management, an estimated $28.2M added.
  • The largest Xenon Pharmaceuticals seller in Q1 2020 was Acuta Capital Partners, an estimated $4.12M sold.

Based on aggregated 13F filings for Q1 2020.